Overview

• Lotte Biologics has officially started full-scale operations at its ADC manufacturing facility at the Syracuse Bio Campus in New York.
• The facility's first contract is with an Asia-based biotech company to produce a clinical-stage antibody-drug conjugate (ADC) candidate.
• Developed with a $100 million investment, the site features integrated production and purification systems, including a 1,000L conjugation reactor, and advanced in-house QC testing capabilities.
• The launch marks the debut of Lotte Biologics' ADC contract development and manufacturing services, offering end-to-end solutions from clinical development to commercial production.
• CEO James Park emphasized plans to ensure a stable supply of high-quality ADC therapeutics and expand the company's global presence as a leading CDMO specializing in ADCs.